Galderma Updates: New Sculptra Campaign, JPAC Launches, and New CFO

Galderma is unveiling We Are All Sculptra, a new program designed to capture the clinical impact of Sculptra (poly-L-lactic acid).

In related news, Galderma launched Restylane Defyne and Restylane Refyne in Japan.

We Are All Sculptra

Through self-recorded video diaries and clinical check-ins, We Are All Sculptra will follow nine patients—who were all new to injectable aesthetics—over two years.

The campaign highlights the diversity of real patients, spanning age, gender identity, ethnicity, and skin biology.

Grounded in Galderma’s AART (Assessment, Anatomy, Range, and Treatment) methodologies and HIT (Holistic Individualised Treatment) protocols, the campaign demonstrates the extent to which regenerative aesthetics can be tailored to individual goals and skin needs, by combining structured clinical assessment with holistic, individualized treatment planning.

“With We Are All Sculptra, we’ll redefine what regenerative biostimulation looks like in real life,” says Alan D. Widgerow, MBBCH, MMED, FCS, FACS, Chief Scientific Officer at Galderma and the Head of the Skin Science Center for Innovation, in a news release. “This program is a bold expression of Galderma’s commitment to science-led personalization, showcasing how Sculptra performs across diverse skin types, treatment approaches, and patient goals. It’s not just about representation; it’s about proving that versatility and inclusivity are inseparable in modern aesthetic medicine.”

The First OBT Hyaluronic Acid Injectables Ever Approved and Launched in Japan

With the new launch in Japan, Restylane Refyne and Restylane Defyne become the first Optimal Balance Technology (OBT) hyaluronic acid injectables ever approved and launched there.

This expands Galderma’s Restylane portfolio in Japan to four products in total, with Refyne and Defyne joining Restylane Classyc and Restylane Lyft.

“The introduction of OBT technology to Japan is a significant milestone not only for clinicians but for the region’s aesthetic landscape as a whole. By combining the power of both [non-animal stabilized hyaluronic acid] NASHA and OBT within the Restylane portfolio in Japan, physicians can tailor treatments more precisely than ever before. This broader set of tools supports natural-looking, expressive outcomes and aligns Japan with international best practice,” says Dr. Stephanie Lam, a Plastic Surgeon in Hong Kong.

The approvals of Restylane Refyne and Defyne in Japan were based on two pivotal, double-blinded, randomized, active-controlled Phase 3 studies investigating the products in 171 and 162 subjects, respectively. Restylane Refyne and Defyne met the studies’ endpoints, demonstrating a clinically meaningful improvement in wrinkle severity for up to 12 months, with most patients reporting at least a one-grade improvement in self-assessment scores after six weeks.

New CFO

Luigi La Corte is Galderma’s new Chief Financial Officer (CFO), effective May 1, 2026.

Mr. La Corte will join Galderma on April 1, 2026 to begin a smooth transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026.

Mr. La Corte recently served as CFO of the global pharmaceutical company Recordati S.p.A from 2019 – 2025. He was appointed to Recordati’s Board of Directors in 2022, a position he continues to hold. Previously, he held a range of senior finance leadership roles within the pharmaceutical sector, including positions at GlaxoSmithKline, AstraZeneca and Alliance Unichem, and served as CFO at Pladis Food Group. Earlier in his career he also worked for Bain & Company, PepsiCo and Procter & Gamble.